Company Neurocrine Biosciences, Inc. Deutsche Boerse AG
Equities
NB3
US64125C1099
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
130 EUR | -1.03% | -0.08% | +9.42% |
Business Summary
Number of employees: 1,448
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceuticals
100.0
%
| 1,489 | 100.0 % | 1,887 | 100.0 % | +26.76% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1,489 | 100.0 % | 1,887 | 100.0 % | +26.76% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 31/12/91 |
Director of Finance/CFO | 44 | 31/10/17 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 29/11/21 |
Eiry Roberts
CTO | Chief Tech/Sci/R&D Officer | 60 | 07/01/18 |
Bill Wilson
COO | Chief Operating Officer | - | 31/08/96 |
Chief Tech/Sci/R&D Officer | 65 | 31/12/92 | |
Gary Lyons
BRD | Director/Board Member | 73 | 31/01/93 |
Todd Tushla
IRC | Investor Relations Contact | - | - |
Ingrid Delaet
LAW | General Counsel | 58 | 31/12/20 |
David Boyer
PRN | Corporate Officer/Principal | 44 | 29/09/19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 31/03/99 |
George Morrow
BRD | Director/Board Member | 72 | 30/09/15 |
Kevin Gorman
FOU | Founder | 66 | 31/12/91 |
Christine Poon
BRD | Director/Board Member | 71 | 10/07/23 |
Chairman | 76 | 07/02/10 | |
Richard Pops
BRD | Director/Board Member | 62 | 31/03/98 |
Gary Lyons
BRD | Director/Board Member | 73 | 31/01/93 |
Leslie Norwalk
BRD | Director/Board Member | 58 | 31/03/98 |
Shalini Sharp
BRD | Director/Board Member | 49 | 02/02/20 |
Johanna Mercier
BRD | Director/Board Member | 54 | 14/04/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 100,637,227 | 98,829,670 ( 98.20 %) | 0 | 98.20 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
VOYAGER THERAPEUTICS, INC. 15.79% | 8,575,316 | 15.79% | 63,628,845 $ |
Company contact information
Neurocrine Biosciences, Inc.
6027 Edgewood Bend Court
92130, San Diego
+858 617 7600
http://www.neurocrine.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+36.24% | 12.55B | |
-24.95% | 8.45B |
- Stock Market
- Equities
- NBIX Stock
- NB3 Stock
- Company Neurocrine Biosciences, Inc.